Literature DB >> 27965982

hsa-miR-376c-3p Regulates Gastric Tumor Growth Both In Vitro and In Vivo.

Lin Tu1, Enhao Zhao1, Wenyi Zhao1, Zizhen Zhang1, Defeng Tang1, Yeqian Zhang1, Chaojie Wang1, Chun Zhuang1, Hui Cao1.   

Abstract

Background. In recent studies, aberrant expression of various microRNAs (miRNAs) is reported to be associated with gastric cancer metastasis. Method. Overexpression construct and inhibitor of hsa-miR-376c-3p were expressed in human gastric adenocarcinoma cell line SGC-7901. The expression level of tumor related genes was detected by qPCR, western blot, and immunostaining. Cell apoptosis was determined by flow cytometry. Xenograft of SGC-7901 cells was used to elucidate the function of hsa-miR-376c-3p in gastric tumor growth in vivo. Result. Expression of hsa-miR-376c-3p was detected in SGC-7901 cells. Downregulation of hsa-miR-376c-3p increased the expression level of BCL-2 and decreased the expression of smad4 and BAD. On the contrary, overexpression of hsa-miR-376c-3p increased the expression of BAD and smad4, while it led to the decreasing expression level of BCL-2. Overexpression of hsa-miR-376c-3p also promoted cell apoptosis in vitro and inhibited gastric tumor growth in vivo. Furthermore, the expression of BCL-2 was higher and expression of smad4 and BAD was lower in tumor tissue than the tissue adjacent to tumor from gastric cancer patients. Conclusion. This study demonstrated that hsa-miR-376c-3p plays an important role in the inhibition of gastric tumor growth and tumor related gene expression both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27965982      PMCID: PMC5124681          DOI: 10.1155/2016/9604257

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Gastric cancer (also known as stomach cancer) is a significant health problem. Globally gastric cancer is the fifth most common malignancy worldwide and the third leading cause of death from cancer across the two genders. Gastric cancer accounts for approximately one million new cases and more than 700,000 cancer-related deaths annually in the world [1-3]. Although several types of treatments have been developed for gastric cancer in clinical trials, drug resistance is still the major issue causing the failure in gastric cancer treatment. Besides the drug resistance, the other vital cause of cancer-related death in gastric cancer patients is metastasis, which involves a series of complex mechanisms [4]. More than half of gastric cancer patients will die within six months due to regional recurrence or distant metastasis [5]. Many signaling molecules such as TGF-β, matrix metalloproteinase- (MMP-) 2, MMP-9, β-catenin, and vascular endothelial growth factor (VEGF) have been shown to affect tumor metastasis [6]. Previous studies indicated that the dysregulation and dysfunction of these signaling pathways leads to mutations in critical genes responsible for the proliferation, apoptosis, and metastasis of malignant gastric tumor cells [7]. Recent studies indicate that abnormal expression of microRNAs (miRNAs) is an important factor for tumor metastasis [8]. miRNA is a small noncoding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses and played critical roles in cancer [9]. Recent studies have identified altered and aberrant regulation of miRNAs in gastric cancer, mediating the tumor growth, metastasis, and invasion [10-15]. Thus, there is a great clinical interest to further investigate the molecular mechanisms of miRNAs aiding in the development of novel strategies for gastric cancer prevention, diagnosis, and treatment in order to improve the clinical outcome of gastric cancer patients. In this study, we investigated the role of hsa-miR-376c-3p in human gastric adenocarcinoma cell line SGC-7901. We found that regulation of hsa-miR-376c-3p played role in the tumor cell growth both in vitro and in vivo. This provided an indication to support the potential clinical application. In the future, the development of hsa-miR-376c-3p as a novel therapeutic target for the treatment of gastric cancer may be applicable.

2. Methods and Materials

2.1. Cell Culture

Human gastric adenocarcinoma cell line SGC-7901 was purchased from Cancer Research Institute of Beijing (China). Cells were cultured in RPMI 1640 medium, supplemented with 10% (v/v) fetal bovine serum, 100 mg/mL penicillin, and streptomycin (all purchased from Life Technologies) at 37°C with 5% CO2.

2.2. Constructs of hsa-miR-376c-3p Inhibitor and Overexpression Plasmid

Inhibitor negative control and hsa-miR-376c-3p inhibitor miRNA were purchased from ABM (Canada). Sequence of hsa-miR-376c-3p was cloned into PCI vector. Cell transfection was conducted by Lipofectamine 2000 (Life Technologies). All the protocol for cell transfection was strictly followed by the product manual.

2.3. Analysis of Cell Cycle Phase by Flow Cytometry

Forty-eight hours following transfection, SGC-7901 cells were resuspended in PBS twice before fixation by adding dropwise to 95% precooled ethanol. Prior to analysis, the cells were warmed, centrifuged at 450 g for 5 min, and resuspended twice in PBS and then stained with PI (containing RNase A at 50 μg/mL) at room temperature in the dark for 30 min. The DNA content was analyzed by flow cytometry using the CellQuest program (Becton-Dickinson and Co., USA).

2.4. Western Blotting

2 μg cell lysates were loaded on each lane of 10% polyacrylamide gel and then blotted onto a polyvinylidene difluoride (PVDF) membrane. After blocking with a PBST containing 5% nonfat dry milk, the membrane was incubated with antibodies against BCL-2, BAD, smad4, and GAPDH (Cell Signaling Technologies, USA). Peroxidase-linked anti-rabbit IgG (Life Technologies) were used as secondary antibodies. These proteins were visualized by using an ECL western blotting detection kit (Amersham Biosciences).

2.5. Xenograft Tumor Models

According to previous study [16], inoculation area of the mice was cleaned and sterilized with ethanol and iodine solutions. SGC-7901 cells (2 × 106 cells in 200 μL PBS) transfected with different constructs were injected subcutaneously into right armpit of 6-week-old BALB/c nude mice. Obvious tumor was observed 4 weeks after cell injection. The implanted mice were observed daily until 60 days. Tumor volume (V) was calculated using the following equation: V = (a 2 × b)/2, where a is the width of the tumor (small diameter) and b is the length (large diameter) (mm).

2.6. Immunohistochemistry

The tumor sections from xenograft tissues were washed in PBS, blocked for 60 min in 0.3% Triton X-100 in phosphate-buffered saline with 5% bovine serum albumin, and then incubated at 4°C with anti-BAD, anti-BCL-2, and anti-smad4 antibodies (purchased from Cell Signaling Technology) overnight. HRP-conjugated secondary antibody was applied to the slides and incubated for 1 hour at room temperature. Lastly, DAB/H2O2 was added to the surface of the slide to develop the color. The slides were visualized by using a Nikon ECLIPSE 90i.

2.7. RNA Extraction and qRT-PCR

Total RNA extraction was performed using TRIzol reagent (Life Technologies) according to the manufacturer's instruction. Two micrograms of total RNA extracted from the cells was subjected to reverse transcription (RT). Synthesis of cDNA was performed by using one-step RT-PCR kit from Takara. SYBR Green (Toyobo) RT-PCR amplification and real time fluorescence detection were performed using ABI 7300 real time PCR thermal cycle instrument (ABI, USA), according to the supplied protocol. Relative gene expression was calculated by the ΔΔCt method.

2.8. Statistical Analysis

Raw data were analyzed using Microsoft Excel software. All data were presented as mean ± standard deviation. The difference among all the groups was determined by paired t-test. A p value less than 0.05 is considered as significantly different and less than 0.01 is considered as very significantly different, while a p value more than 0.05 is considered as not significantly different.

3. Results

3.1. hsa-miR-376c-3p Regulated SGC-7901 Cell Apoptosis

To elucidate the role of hsa-miR-376c-3p in gastric tumor growth, we firstly determined the expression level of hsa-miR-376c-3p and smad4 in four cell lines. The quantitative reverse transcription PCR result indicated that both hsa-miR-376c-3p and smad4 were expressed in the gastric cancer cell line (Figure 1(a)). Since hsa-miR-376c-3p was expressed in the gastric adenocarcinoma cell line SGC-7901, we determined whether the regulation of hsa-miR-376c-3p affected the cell viability. The hsa-miR-376c-3p overexpression group exhibited the enhanced cell apoptosis (Figure 1(b)) and increases the cell ratio at G1 phase (Figure 2(a)) compared to the nontransfected group (Figures 1(c) and 2(b)) and empty vector group (Figures 1(d) and 2(c)); however, there is no significant difference.
Figure 1

(a) Real time PCR results indicated the expression of hsa-miR-376c-3p and smad4 in four different gastric cancer cell lines. Measurement of apoptotic cell ratio was conducted by flow cytometry in hsa-miR-376c-3p overexpressed (b), nontransfected (c), and empty vector-transfected (d) SGC-7901 cells.

Figure 2

Cell cycle analysis was performed by flow cytometry in hsa-miR-376c-3p overexpressed (a), nontransfected (b), and empty vector-transfected (c) SGC-7901 cells.

BAD/BCL-2 signaling was involved in hsa-miR-376c-3p-mediated apoptosis Furthermore, we found the regulation of hsa-miR-376c-3p could alter the expression level of some cancer-related genes. As shown in Figure 3(a), the miRNA inhibition drastically decreased the mRNA level of apoptotic gene BAD and increased the antiapoptotic gene BCL-2. However, no significant expression alteration in smad4 was observed compared to scramble control group. Besides, the miRNA overexpression significantly increased the protein expression level of apoptotic gene BAD and decreased the antiapoptotic gene BCL-2 (Figure 3(b)). Collectively, these results indicated that hsa-miR-376c-3p expression regulated the gastric tumor cell growth in vitro through BAD/BCL-2 pathway.
Figure 3

The expression alteration of BAD and BCL-2 was determined by real time PCR (a) and western blotting (b) in hsa-miR-376c-3p inhibitor transfected, nontransfected, and scramble control-transfected SGC-7901 cells. The significance was calculated by paired t-test. “ns” represented not significant. p < 0.01.

3.2. Overexpression of hsa-miR-376c-3p Inhibited the Gastric Tumor Growth In Vivo

Next, we detected the effect of hsa-miR-376c-3p on gastric tumor growth in vivo. Xenograft of SGC-7901 cells leads to the tumor information in the BALB/c nude mice (Figure 4(a)). Xenograft of SGC-7901 cells transfected with empty vector did not change the tumor size, while the overexpression of hsa-miR-376c-3p negatively affected the in vivo tumor growth compared to the controls (Figure 4(a)). Besides, the western blotting data showed that overexpression of hsa-miR-376c-3p increased the expression of BAD and smad4 and decreased the antiapoptotic gene BCL-2 (Figure 4(b)). However, the transfection of empty vector did not show any significant change in those tumor related proteins (Figure 4(b)). Besides, immunostaining result further confirmed expression alteration in smad4, BAD, and BCL-2 when hsa-miR-376c-3p was overexpressed (Figure 5).
Figure 4

(a) Tumor samples from xenograft of wide type, empty vector-transfected, and hsa-miR-376c-3p overexpressed SGC-7901 cells. (b) Western blotting showed the expression change of smad4, BAD, and BCL-2 among three different groups.

Figure 5

Immunostaining analysis indicated expression alteration in smad4 (a–c), BAD (d–f), and BCL-2 (g–i) in tumor sections from xenograft of wide type, empty vector-transfected, and hsa-miR-376c-3p overexpressed SGC-7901 cells.

3.3. Expression of hsa-miR-376c-3p in Tumor Samples from Gastric Cancer Patients

Finally, we collected three samples from three patients with gastric cancer. The real time PCR results indicated that the expression level of hsa-miR-376c-3p was significantly lower in tumor tissues compared to the tissues adjacent to tumors (Figure 6(a)). Furthermore, the mRNA expression of smad4 and BAD protein was significantly higher in adjacent tissues than in tumors, whereas the expression of BCL-2 was significantly lower in adjacent tissues than in tumors (Figure 6(a)). Similar results were obtained in all six patient samples in terms of the protein expression of BAD and BCL-2 (Figure 6(b)).
Figure 6

Expression change of hsa-miR-376c-3p, smad4, BAD, and BCL-2 in tumor tissue and tissue adjacent with tumor collected from gastric cancer patients was determined by real time PCR (a) and western blotting (b). The significance was calculated by paired t-test. p < 0.05; p < 0.01.

4. Discussion

The aberrant expression of miRNAs is involved in many diseases, including gastric cancer. In this study, we used hsa-miR-376c-3p inhibitor and overexpression construct to elucidate the role of hsa-miR-376c-3p in the gastric cancer cell apoptosis. Furthermore, we also indicated that overexpression of hsa-miR-376c-3p had an antigastric tumor effect in vivo. In recent years, many studies have disclosed the dual role of miRNAs as oncogenes or tumor suppressor genes through activating multiple cellular signaling pathways, related with tumorigenesis, progression, and metastasis [17-20]. However, only limited number of studies showed specific miRNAs involved in human tumor formation in vivo. From this study, a previously unidentified miRNA hsa-miR-376c-3p was shown to be closely correlated with gastric cancer development and progression. More importantly, xenograft experiment indicated that gastric tumor growth was inhibited when the tumors were overexpressed in gastric cancer cells, suggesting that hsa-miR-376c-3p may serve as a tumor suppressor gene in gastric cancer. Furthermore, our in vitro data showed that hsa-miR-376c-3p overexpression could lead to the promotion of apoptosis and G1 arrest in gastric cancer cells. This process was correlated with the increasing expression of BAD and decreasing expression of BCL-2. This suggested that hsa-miR-376c-3p induced apoptosis was mediated by BCL-2/BAD death pathway. BCL-2 is a crucial regulator of the mitochondrial dependent pathway of apoptosis. It has antiapoptotic function, preventing cytochrome c release from mitochondrion to cytosol [21]. The BCL-2-associated death promoter (BAD) protein is a proapoptotic member of the BCL-2 gene family which is involved in initiating apoptosis [22]. This raised the possibility that hsa-miR-376c-3p was a new target and provided a new strategy to treat malignant tumors, including gastric cancer. Further study will be focused on clarifying more specific mechanisms underlying the roles of hsa-miR-376c-3p in the progression and invasion of gastric cancer as well as to assess its function in clinical context.
  22 in total

1.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

2.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

3.  MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.

Authors:  Ling Ding; Yanjun Xu; Wei Zhang; Yujie Deng; Misi Si; Ying Du; Haomi Yao; Xuyan Liu; Yuehai Ke; Jianmin Si; Tianhua Zhou
Journal:  Cell Res       Date:  2010-06-15       Impact factor: 25.617

4.  Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer.

Authors:  Kuo-Wang Tsai; Chew-Wun Wu; Ling-Yueh Hu; Sung-Chou Li; Yu-Lun Liao; Chun-Hung Lai; Hsiao-Wei Kao; Wen-Liang Fang; Kuo-Hung Huang; Wen-Ching Chan; Wen-Chang Lin
Journal:  Int J Cancer       Date:  2011-12-01       Impact factor: 7.396

5.  MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.

Authors:  Jun Tie; Yanglin Pan; Lina Zhao; Kaichun Wu; Jie Liu; Shiren Sun; Xuegang Guo; Biaoluo Wang; Yi Gang; Yongguo Zhang; Quanjiang Li; Taidong Qiao; Qingchuan Zhao; Yongzhan Nie; Daiming Fan
Journal:  PLoS Genet       Date:  2010-03-12       Impact factor: 5.917

6.  miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2.

Authors:  Wha Ja Cho; Jeong Min Shin; Jong Soo Kim; Man Ryul Lee; Ki Sung Hong; Jun-Ho Lee; Kyoung Hwa Koo; Jeong Woo Park; Kye-Seong Kim
Journal:  Mol Cells       Date:  2009-11-19       Impact factor: 5.034

7.  miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation.

Authors:  Mei Wang; Hongbing Gu; Hui Qian; Wei Zhu; Chonghui Zhao; Xu Zhang; Yang Tao; Ling Zhang; Wenrong Xu
Journal:  Eur J Cancer       Date:  2013-01-16       Impact factor: 9.162

8.  Effectiveness of local injection of lentivirus-delivered stathmin1 and stathmin1 shRNA in human gastric cancer xenograft mouse.

Authors:  Javed Akhtar; Zhou Wang; Che Yu; Zhi Ping Zhang
Journal:  J Gastroenterol Hepatol       Date:  2014-09       Impact factor: 4.029

9.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.

Authors:  Sandrine Sander; Lars Bullinger; Kay Klapproth; Katja Fiedler; Hans A Kestler; Thomas F E Barth; Peter Möller; Stephan Stilgenbauer; Jonathan R Pollack; Thomas Wirth
Journal:  Blood       Date:  2008-08-19       Impact factor: 22.113

10.  Changes in circulating microRNA levels associated with prostate cancer.

Authors:  R J Bryant; T Pawlowski; J W F Catto; G Marsden; R L Vessella; B Rhees; C Kuslich; T Visakorpi; F C Hamdy
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

View more
  9 in total

1.  Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes.

Authors:  Yury O Nunez Lopez; Berta Victoria; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2017-11-20

2.  Potential role of circular RNA in cyclosporin A-induced cardiotoxicity in rats.

Authors:  Yanru Zhao; Yang Li; Dachuan Fan; Jinxiao Hou; Yunpeng Bai; Chenguang Dai; Xue Cao; Hai Qi; Bingchen Liu
Journal:  J Appl Toxicol       Date:  2021-05-25       Impact factor: 3.628

3.  In silico identification of microRNAs predicted to regulate N-myristoyltransferase and Methionine Aminopeptidase 2 functions in cancer and infectious diseases.

Authors:  Ranjit Chauhan; David Datzkiw; Shailly Varma Shrivastav; Anuraag Shrivastav
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

4.  Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis.

Authors:  Shaojian Lin; Langping Tan; Dingyuan Luo; Xinzhi Peng; Yue Zhu; Honghao Li
Journal:  Cancer Manag Res       Date:  2019-09-19       Impact factor: 3.989

5.  Upregulation of miR-376c-3p alleviates oxygen-glucose deprivation-induced cell injury by targeting ING5.

Authors:  Heng Zhang; Jie Zhou; Mingxia Zhang; Yanjie Yi; Bing He
Journal:  Cell Mol Biol Lett       Date:  2019-12-04       Impact factor: 5.787

6.  Gene co-expression network for analysis of plasma exosomal miRNAs in the elderly as markers of aging and cognitive decline.

Authors:  Zheng Ye; Bo Sun; Xue Mi; Zhongdang Xiao
Journal:  PeerJ       Date:  2020-01-06       Impact factor: 2.984

7.  MiR-450a-5p Inhibits Gastric Cancer Cell Proliferation, Migration, and Invasion and Promotes Apoptosis via Targeting CREB1 and Inhibiting AKT/GSK-3β Signaling Pathway.

Authors:  Ya-Jun Zhao; Jun Zhang; Yong-Cang Wang; Liang Wang; Xin-Yang He
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

8.  Construction of a circRNA-miRNA-mRNA Regulatory Network for Coronary Artery Disease by Bioinformatics Analysis.

Authors:  Zebo Zhang; Haiyan Qian; Li Wang; Zhenbo Tao; Keai Cheng; Kaiyue Wang; Yanqing Xie; Lina Zhang
Journal:  Cardiol Res Pract       Date:  2022-02-16       Impact factor: 1.866

9.  Targeted MicroRNA Profiling in Gastric Cancer with Clinical Assessement.

Authors:  H Pehlevan Özel; T Dinç; R S Tiryaki; A G Keşküş; Ö Konu; S I Kayilioğlu; F Coşkun
Journal:  Balkan J Med Genet       Date:  2022-06-05       Impact factor: 0.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.